Generate Biomedicines
Clinical-stage generative biology company that integrates machine learning, large-scale experimental biology, and structural validation to design and advance protein-based therapeutics. The organization operates a computationally driven design platform coupled to high-throughput wet-lab experimentation to generate antibodies, multispecific proteins, CAR T constructs and other protein modalities, and advances selected programs through early- and late-stage clinical trials.
Industries
Nr. of Employees
large (251-1000)
Generate Biomedicines
Somerville, Massachusetts, United States
Patents
Products
GB-0895 (TSLP-binding monoclonal antibody)
Investigational monoclonal antibody designed to bind and neutralize thymic stromal lymphopoietin (TSLP) for airway inflammatory diseases; engineered for extended half-life and evaluated in clinical development for severe asthma and COPD.
GB-4362 (antibody to sequester free cytotoxic payload)
Monoclonal antibody designed to selectively bind free monomethyl auristatin E (MMAE) to reduce circulating free payload associated with systemic toxicities from MMAE-based antibody–drug conjugates without interacting with intact conjugates.
GB-5267 (IL‑18-armored CAR T targeting MUC16)
Investigational armored CAR T-cell therapy targeting membrane-bound MUC16 and co-expressing IL-18 to enhance T-cell activation, proliferation and persistence; under early clinical evaluation for platinum-resistant metastatic ovarian cancer.
GB-0669 (broadly neutralizing antibody against SARS-CoV-2 S2 stem)
Monoclonal antibody engineered to target a conserved S2 stem epitope to provide broad neutralization of SARS-CoV-2 variants and related sarbecoviruses; evaluated for safety, pharmacokinetics and ex vivo neutralization with extended half-life engineering.
GB-0895 (TSLP-binding monoclonal antibody)
Investigational monoclonal antibody designed to bind and neutralize thymic stromal lymphopoietin (TSLP) for airway inflammatory diseases; engineered for extended half-life and evaluated in clinical development for severe asthma and COPD.
GB-4362 (antibody to sequester free cytotoxic payload)
Monoclonal antibody designed to selectively bind free monomethyl auristatin E (MMAE) to reduce circulating free payload associated with systemic toxicities from MMAE-based antibody–drug conjugates without interacting with intact conjugates.
GB-5267 (IL‑18-armored CAR T targeting MUC16)
Investigational armored CAR T-cell therapy targeting membrane-bound MUC16 and co-expressing IL-18 to enhance T-cell activation, proliferation and persistence; under early clinical evaluation for platinum-resistant metastatic ovarian cancer.
GB-0669 (broadly neutralizing antibody against SARS-CoV-2 S2 stem)
Monoclonal antibody engineered to target a conserved S2 stem epitope to provide broad neutralization of SARS-CoV-2 variants and related sarbecoviruses; evaluated for safety, pharmacokinetics and ex vivo neutralization with extended half-life engineering.
Expertise Areas
- Generative biology and protein design
- Protein engineering for therapeutics (antibodies, multispecifics, enzymes, cytokines)
- Cell therapy engineering and CAR T design
- mRNA therapeutics and lipid nanoparticle delivery
Key Technologies
- Diffusion-based generative models for proteins
- Equivariant graph neural networks for molecular structure
- LLM-driven workflow orchestration
- High-throughput cell-based screening platforms
News & Updates
First-in-human dosing milestone for an armored CAR T-cell therapy designed for solid tumors, marking transition of a platform-designed CAR into clinical testing.
Preprint and supporting blog describing rational and LLM-aided refactoring of CAR signaling domains that yielded shorter constructs with improved expression and T-cell functional properties.
Multi-target strategic collaboration to design and develop multispecific protein therapeutics for obesity and metabolic diseases using the design platform; financial terms and milestone structure disclosed.
First external equity raise of $370 million announced to advance the platform and scale computational and wet-lab capabilities.
Company completed an IPO to raise capital to advance platform and pipeline.
Multi-target collaboration leveraging the generative platform to create protein therapeutics; transaction included upfront payment and milestone structure.
First-in-human dosing milestone for an armored CAR T-cell therapy designed for solid tumors, marking transition of a platform-designed CAR into clinical testing.
Preprint and supporting blog describing rational and LLM-aided refactoring of CAR signaling domains that yielded shorter constructs with improved expression and T-cell functional properties.
Multi-target strategic collaboration to design and develop multispecific protein therapeutics for obesity and metabolic diseases using the design platform; financial terms and milestone structure disclosed.
First external equity raise of $370 million announced to advance the platform and scale computational and wet-lab capabilities.
Company completed an IPO to raise capital to advance platform and pipeline.
Multi-target collaboration leveraging the generative platform to create protein therapeutics; transaction included upfront payment and milestone structure.